Sanofi - 10 Aug 2026 Form 4 Insider Report for Latigo Biotherapeutics, Inc. (LTGO)

Reporting relationship: 10%+ Owner
Issuer ticker: LTGO
Reported as of: 10 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2026, 08:18:46 UTC
Prior SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Alexandra Roger, as attorney-in-fact for Sanofi

Key filing fact

Sanofi filed Form 4 for Latigo Biotherapeutics, Inc. (LTGO) on 12 Aug 2026.

Key facts

This page summarizes Sanofi's Form 4 filing for Latigo Biotherapeutics, Inc. (LTGO).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 08:18.

Change

Previous filing in this sequence was filed on 12 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001121404 Primary reporting owner

Sanofi

Relationship: 10%+ Owner
Address: 46 AVENUE DE LA GRANDE ARMEE, PARIS, FRANCE
Signature: /s/ Alexandra Roger, as attorney-in-fact for Sanofi
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LTGO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +494,800
Change %
Price
Shares after: 494,800
Date: 10 Aug 2026
Ownership: See footnote
Footnotes: F1, F3

LTGO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +177,978
Change %: +36%
Price
Shares after: 672,788
Date: 10 Aug 2026
Ownership: See footnote
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LTGO transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -494,800
Change %: -100%
Price
Shares after: 0
Date: 10 Aug 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 494,800
Exercise price
Footnotes: F1, F3

LTGO transaction Derivative

Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares: -177,978
Change %: -100%
Price
Shares after: 0
Date: 10 Aug 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 177,978
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Sanofi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration.

Footnote F2

The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock.

Footnote F3

Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.

SEC remarks

Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock. The convertibility and expiration of the Preferred Stock and Note prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 12, 2026.